A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

Cystic Fibrosis Clinical Trial

Official title:

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00332215
• Other study ID #: 0511M77511
• Secondary ID: CSI-N115-I-010-0
• Status: Terminated
• Phase: Phase 1
• First received: May 30, 2006
• Last updated: November 26, 2008
• Start date: February 2006

Study information

• Verified date: November 2008
• Source: University of Minnesota - Clinical and Translational Science Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by FEV1, or reduce inflammatory markers in induced sputum of people with CF.

Description:

Cystic fibrosis (CF) is a disease that causes airway blockage and infection that damages the lung. The lungs of CF patients are frequently loaded with inflammatory cells, damaging proteins and oxidants. Oxidants are molecules that contain oxygen and are capable of disrupting cells and tissue. The CF protein is involved in the transport of the important antioxidant glutathione (GSH). Antioxidants are molecules that block oxidants and render them inactive. The absence of this protection in the airways makes them prone to damage from oxidants. Sodium pyruvate is part of the body's natural anti-oxidant defense system. Sodium pyruvate reacts directly with oxygen radicals to neutralize them and increases cellular levels of glutathione.

The purpose of this study is to investigate the safety and tolerability of 3 different single dose levels of sodium pyruvate administered via a nebulizer to persons with CF lung disease.

This will be a phase I study with 3 stages. In the first stage subjects will receive one of 3 possible doses of the active drug only once. In the second stage subjects will receive 2 doses of the active drug 12 hours apart. In the third stage subjects will receive either active drug or placebo every 12 hours for 4 weeks.

For stage 1 subjects will come to the University of Minnesota's General Clinical Research Center (GCRC) for a screening visit. They will return to the GCRC 1 to 7 days later for a baseline assessment that will be followed by study drug administration. The subject will be observed for 4 hours and safety parameters will be obtained.

For stage 2 subjects will come to the GCRC for a screening visit. They will return to the GCRC 1 to 7 days later for a baseline assessment that will be followed by study drug administration. Safety parameters will be obtained for the following 4 hours. 12 hours after the first dose was given the subject will receive a second dose and safety parameters will again be obtained over the next 4 hours.

For stage 3 subjects will come to the GCRC for a screening visit. They will return to the GCRC 1 to 7 days later for a baseline assessment that will be followed by study drug administration. Safety parameters will be obtained for the following 4 hours. The subject will be sent home to continue on study drug every 12 hours for the following 4 weeks. The subject will be asked to return to the GCRC once a week for safety assessments.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 70
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of CF using Cystic Fibrosis Foundation criteria.

• FEV1 >40% predicted

• Colonization with Pseudomonas aeruginosa - (>= 2 positive cultures over past 12 months)

• >18 years of age

• Stable respiratory status without dyspnea at rest

• Non-smoker

• Able to perform sputum induction

Exclusion Criteria:

• Severe CF lung disease with an FEV1 of <40% predicted

• Lung disease not CF related

• Positive culture for Burkholderia cepacia over previous 2 years

• Active allergic bronchopulmonary aspergillosis

• Clinically significant cardiac disease

• Pregnancy

• Females of child bearing age not using contraception

• Females lactating

• <18 years of age

• Systemic steroid treatment within 1 month

• Hospitalization within 3 months due to airway disease

• Immunotherapy

• Changes in respiratory medication use within 1 month

• New medications within 1 month

• Administration of any investigational drug or device within 28 days of visit 1 or within 6 half-lives of the investigational drug (whichever is longer).

• History of significant (>60 cc) hemoptysis within 1 year

• Poorly controlled insulin dependent diabetes mellitus

• Acute respiratory illness within 1 month

• Use of tobacco products or recreational drugs

• History of adverse reaction to sputum induction

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• Inhaled Sodium Pyruvate

Locations

Country	Name	City	State
United States	University of Minnesota General Clinical Research Center	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Minnesota - Clinical and Translational Science Institute	Cellular Sciences

Country where clinical trial is conducted

United States, 

References & Publications (2)

O'Donnell-Tormey J, Nathan CF, Lanks K, DeBoer CJ, de la Harpe J. Secretion of pyruvate. An antioxidant defense of mammalian cells. J Exp Med. 1987 Feb 1;165(2):500-14. — View Citation

Votto J, Bowen J, Metersky M, Thrall R. Effect of Inhaled Sodium Pyruvate in Patients with Mild Bronchial Asthma. Am J Resp Crit Care Med 2001, 163 (5S):A860.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome variable is the assessment of safety of inhaled sodium pyruvate in subjects with CF.Subjects will be evaluated for the presence of symptoms and safety laboratory measurements.
Secondary	The secondary outcome variable is the determination of improvement in lungs of CF subjects as determined by measurement of FEV1 and measurement of inflammatory markers in induced sputum.